Data Sheet

Product Name:	BTX161
Cat. No.:	CS-0069459
CAS No.:	2052301-24-1
Molecular Formula:	$C_{15}H_{16}N_2O_3$
Molecular Weight:	272.30
Target:	Casein Kinase
Pathway:	Cell Cycle/DNA Damage; Stem Cell/Wnt
Solubility:	DMSO : 25 mg/mL (91.81 mM; ultrasonic and warming and heat to 60°C)



BIOLOGICAL ACTIVITY:

BTX161, a Thalidomide analog, is a potent **CKIα** degrader. BTX161 mediates degradation of CKIα better than Lenalidomide in human AML cells and activates DNA damage response (DDR) and p53, while stabilizing the p53 antagonist MDM2[1]. **In Vitro:** BTX161 (25 μM; 4 hours; MV4-11 cells) upregulates all the Wnt targets including MYC and did not affect MDM2 mRNA expression[1]. BTX161 (10 μM; 6 hours; MV4-11 cells), on its own, augmented p53 and MDM2 protein expression, yet in combination with THZ1, and particularly with both THZ1 and CDK9, further augmented p53 and induced maximal caspase 3 activation[1].

References:

[1]. Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018;175(1):171-185.e25.

CAIndexNames:

1H-Azepine-2,7-dione, 3-(1,3-dihydro-4-methyl-1-oxo-2H-isoindol-2-yl)tetrahydro-, (3S)-

SMILES:

O=C([C@@H](N(CC1=C2C=CC=C1C)C2=O)CCC3)NC3=O

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA